Expression of large numbers of different costimulatory intetumor-specific cytolytic T cell (CTL) activity involving both grin ligands (CILs) attributes dendritic cells with an ability the perforin and Fas-ligand pathways. Adoptive transfer of to induce primary anti-tumor immune responses. Here, we splenocytes from cured mice rapidly cleared established show that optimized gene transfer of the xenogeneic tumors in recipients. The mechanism for CIL-mediated (human) CILs VCAM-1, MAdCAM-1 and ICAM-1 causes immunity is unknown, but may involve CTL-facilitated rapid and complete rejection of established mouse EL-4 tumor lysis, since CTLs were generally twice as efficient at tumors, and generates prolonged systemic anti-tumor killing CIL-transfected tumor cells than parental tumor cells. immunity; whereas human E-cadherin weakly slows tumor Optimized CIL-based gene therapy may provide an growth. In each case the immune response was mediated approach to complement or replace conventional DC by CD8
Introduction
Dendritic cells can provide valuable lessons in how to fight cancer, as they initiate the primary immune response and control the functions of effector B and T cells. 1 The efficacy of DCs in T cell binding and activation relates, in part, to their expression of high levels of a large number of different cell adhesion molecules (CAMs) [2] [3] [4] capable of costimulating T cell proliferation, including CD58/LFA-3, VCAM-1, ICAM-1, ICAM-3, 5 MAdCAM-1, 6 B7.1, B7.2, 4-1BB ligand, 7 RANK ligand, 8 MRC-OX-2, 9 and E-cadherin. 10 Such DC-derived immunoregulatory molecules could be employed to combat cancer and inflammatory disease, and could offer improved immunotherapeutic benefit over and above that already demonstrated with living DC-based vaccines. 11 Transfection of the CD28/CTLA-4 ligands B7.1 and B7.2 into immunogenic tumor cells attributes such cells with an ability to present their tumor antigens and to generate anti-tumor cytotoxic T lymphocytes (CTL), whereas the immune system remains completely ignorant of the parental tumor cells. [12] [13] [14] [15] Similarly, transduction of tumor cells with the costimulatory integrin ligand (CIL) ICAM-1 (ligand for LFA-1 integrin), and the tumor necrosis factor-like ligand 4-1BBL suppresses tumorigenicity and generates protective anti-tumor immunity. 16, 17 Thus, gene transfer into tumors of three DC costimulatory molecules, which have been reported to stimulate We have demonstrated that recombinant solubilised immunoglobulin Fc-fusion forms of mouse MAdCAM-1, human VCAM-1 (ligands for VLA-4 and LPAM-1 integrins), and mouse E-cadherin (ligand for HML-1 integrin), in addition to human ICAM-1, mouse B7.1, and human B7.2 can costimulate the activation of CD4 + T cells in vitro. 18, 19 VCAM-1, and ICAM-1 were found to be the most potent costimulators, and interestingly VCAM-1, MAdCAM-1, and ICAM-1 have the unique ability to costimulate 'remotely', that is they retain their ability to costimulate when presented on an entirely different surface from the stimulating anti-CD3. 18 We have therefore analysed the effects of VCAM-1, MAdCAM-1 and Ecadherin expression on tumor growth in vivo, revealing that multiple CIL have anti-tumor activity, and could be employed to either enhance or replace conventional DC adoptive therapy.
Results
Optimization of gene transfer of CILs to induce rejection of established tumors EL-4 tumors were established in mice and injected with B7.1 and ICAM-1 DNA/liposome complexes diluted in water, PBS, 5% glucose, or 5% glucose in 0.01% Triton X-100 to determine the optimal diluent for gene transfer. The latter diluent markedly enhanced the anti-tumor activity of both B7.1 and ICAM-1, such that tumors began shrinking within 2 days. The rate of tumor rejection was significant 7 (P Ͻ 0.05) and highly significant 14 (P Ͻ 0.001) days after gene injection, and by day 21 all tumors had virtually disappeared (Figure 1a) . In contrast, all other diluents led to slow, but progressive tumor growth. Gene transfer of 60 g plasmid DNA appeared optimal (Figure 1b) , and was used with the 5% glucose/0.01% Triton X-100 throughout the following study.
Multiple CILs stimulate anti-tumor immunity and generate a systemic memory response Human VCAM-1, ICAM-1, and human and mouse MAd-CAM-1 and E-cadherin were examined for their ability to stimulate anti-tumor immune responses, and were compared with the established anti-tumor agents mouse B7.1 and human B7.2. Established tumors (0.1-0.2 cm) treated with B7.1, B7.2, VCAM-1, human MAdCAM-1, and ICAM-1 failed to grow (P Ͻ 0.001) (Figure 2a) , and mice remained tumor-free for at least 2 months. In contrast, mouse MAdCAM-1 significantly (P Ͻ 0.05) slowed tumor growth, whereas growth inhibition by human Ecadherin was not significant (P Ͼ 0.05). Tumors treated with mouse E-cadherin and empty vector grew unchecked. Gene transfer resulted in the expression of CILs in Ͼ80% of cells (Figure 2b ; similar results were also obtained with the FITC-labelled anti-mouse B7.1 mAb 1G10, data not shown).
Animals previously cured by gene therapy completely rejected the challenge of 1 × 10 5 parental tumor cells for the 36 days they were monitored (Table 1) . In contrast, uncured animals whose tumors had been treated previously with human E-cadherin, failed to reject the parental tumor challenge (data not shown). As expected all animals failed to resist the challenge of the very large tumor burden of 5 × 10 7 cells. However human MAd- Figure 3 ). Mouse MAdCAM-1 and human E-cadherin generated less CTL activity, whereas mouse E-cadherin had negligible effect. Anti-tumor CTL activity was also measured 36 days following challenge with parental tumor cells ( Table 1) . Challenge with 1 × 10 5 tumor cells generated profiles very similar to those measured 28 days after initial gene transfer. Surprisingly, challenge with the large tumor burden of 5 × Effector:target cell ratio. 
Figure 3 Comparison of anti-tumor CTL activity generated by gene transfer of different costimulators. Splenocytes were removed from animals 28 days following CIL gene transfer and were tested for cytolytic activity against EL-4 tumor cells. The percentage cytotoxicity is plotted against various effector to target (E:T) ratios. Control animals received empty

cells (Figure 5a). Simultaneous depletion of both CD8
+ T cells and NK cells resulted in completely unchecked tumor growth, similar to that in untreated controls ( Figure 5d ). Tumors began to regress 1 week after suspending anti-CD8, and anti-NK cell antibody treatment, but the mice never became tumor-free during the 21 day period they were monitored (data not shown).
CILs facilitate initial tumor cell lysis
To assess whether expression of CILs facilitates CTLmediated tumor cell lysis, an in vitro CTL killing assay was devised where splenocytes from animals with B7.1-treated tumors were mixed with disaggregated EL-4 cells that had been isolated (2 days after gene transfer) from the tumors of animals treated with a variety of CILs. Disaggregated EL-4 cells expressed the CAMs at high levels where 80-85% of cells were positive (Figure 6a ). At an effector to target ratio of 25:1, CTL showed highly significant (P Ͻ 0.001) killing of tumor cells transfected with human VCAM-1, ICAM-1, MAdCAM-1, B7.2 and mouse B7.1 than parental EL-4 cells (Figure 6b ). In general, they were twice as efficient at killing transfected tumor cells versus parental cells. Mouse E-cadherin and MAdCAM-1 expressing tumor cells were also significantly (P Ͻ 0.05) better targets. Abrogation by anti-CIL antibodies of the enhanced sensitivity of transduced tumor cells to CTLmediated lysis was highly significant (P Ͻ 0.001) (Figure 6b ).
Anti-tumor CTL employ both the Fas-ligand and perforin pathways to kill EL-4 target cells
The in vitro CTL killing assay was utilized to evaluate the cytotoxic mechanisms of CIL-mediated tumor rejection. Inclusion of EGTA/MgCl 2 , which specifically blocks the Ca ++ -dependent perforin pathway, led to partial inhibition of tumor-specific CTL activity ( Figure 7 ). Pretreatment of splenocytes with the neutralizing anti-Fas-ligand mAb MFL3 was even more effective at blocking CTL activity, whereas simultaneous blocking of both the perforin and Fas-ligand pathways dramatically inhibited (P Ͻ 0.001) the CTL activity of all animals examined.
Discussion
Multiple CILs have therapeutic potential in treating cancer Here we have demonstrated for the first time that gene transfer of human VCAM-1 and MAdCAM-1 into established tumors is as effective as B7.1, B7.2 and ICAM-1, which have previously been demonstrated to have antitumor activity.
12-16 Successful treatment depended on the amount of DNA for gene transfer, the DNA diluent, the xenogenicity of CILs, and tumor size. Whereas a range of doses of each costimulator gene were inhibitory for tumor growth, 60 g of DNA injected into 1 mm tumors was optimal for rapid tumor regression, reflecting a requirement to maximise transfection efficiencies or optimise expression of CILs. The diluent 5% glucose in 0.01% Triton X-100 was optimal, as described previously to introduce a reporter gene into mouse melanoma BL6 tumors. 20 Xenogeneic forms of CILs were found to have greater anti-tumor activity than syngeneic forms. Thus whereas mouse MAdCAM-1 only weakly slowed tumor growth, human MAdCAM-1 caused rapid tumor rejection, and generated anti-tumor systemic immunity. Similarly, mouse E-cadherin was totally without effect, but its human homologue very weakly slowed tumor growth. These results are in agreement with those of Wei et al 16 who found that rat tumor cell lines engineered to express human ICAM-1 stimulated anti-tumor immunity in rats, whereas rat ICAM-1-expressing tumor cells were not effective. It was argued that human ICAM-1 provides sufficient stimulatory signals due to both its costimulatory function, and its inherent antigenicity as a foreign antigen. In contrast in a mouse model of neuroblastoma, transfection of the mouse ICAM-1 gene into tumors reduced their tumorigenicity. 21 Further experiments are required to dissect the contributions of 'foreigness' versus T cell costimulation in generating anti-tumor immunity. Mouse B7.1 generates protection against mouse tumors, suggesting that its T cell costimulatory function can be sufficient. In contrast human E-cadherin is only very weakly protective, indicating that 'foreigness' alone is not sufficient. Xenogeneic CILs may somehow break tolerance and thereby overcome immunological ignorance of tumors. Immunization of mice with purified syngeneic melanoma antigen gp75 failed to elicit antibody or cytotoxic T cell responses, whereas immunization with human gp75 elicited autoantibodies to syngeneic gp75 leading to rejection of metastatic melanomas. 22 In our experiments, anti-tumor humoral immunity was not detected, as serum taken from cured animals had no protective effect when injected into recipient animals (data not shown).
We have consistently found that gene transfer of CILs into tumors less than 0.3 cm in diameter causes rapid tumor rejection, whereas tumors become increasingly refractory to treatment as their size increases. Larger tumors appear actively to suppress or avoid the immune response, since challenge of cured animals with large tumor burdens led to reductions in the levels of antitumor CTL activity compared with the response to smaller burdens. The mechanisms responsible are unknown, but could include the increased secretion of immunosuppressive cytokines such as TGF-␤, 23 or metalloproteases which release latent TGF-␤ from extracellular stores, loss of tumor antigens, or acquisition of resistance to killing. Alternatively, we have observed that EL-4 cells begin to express cell-surface Fas-ligand as cell density increases, whereas Fas is expressed at a constant level (data not shown). Fas-expressing EL-4 tumor cells may kill responding anti-tumor CTL, 24, 25 and thereby impair the anti-tumor immune response. A further explanation would be that certain EL-4 cells within the larger secondary tumor challenges may have distinct antigenic profiles unrelated to that of cells in the original primary tumor challenge, and hence are not susceptible to killing by antitumor memory CTL. Repeated CIL gene transfer into tumor regrowths arising from antigenic drift could potentially exhaust the heterogeneity of a tumor, and provide protective immunity for the life of an animal. CIL gene transfer into tumors arising from rechallenge of cured animals with a large tumor burden led once again to complete tumor rejection (data not shown), in support of the latter notion.
That CILs facilitate tumor cell lysis was shown by the fact that EL-4 cells transduced with the various CILs were better targets for anti-tumor CTL than unmodified EL-4 cells. There is now a large body of evidence showing that ICAM-1 expression on tumor cells enhances tumor susceptibility to lysis by CTL, 21, [26] [27] [28] and more recently ICAM-1 and B7.1 expression was found to induce MHCunrestricted killing of target cells by promiscuous CTLs. 29 Low expression of VCAM-1 on the lymphokine-activated killer (LAK)-resistant cell line OKM-2T has been suggested to be partly involved in resistance to lysis by LAK cells. 30 Our results demonstrate for the first time that MAdCAM-1 and E-cadherin also play a role in target cell lysis by CTL.
While all the CAMs seem to increase the cytotoxicity of CTL towards the tumor cells, not all are effective in the rejection of the tumor. They presumably increase cytotoxicity by enhancing conjugate formation between tumor cells and antitumor CTL. However, conjugate formation alone may not be sufficient initially to generate anti-tumor CTL. We have previously demonstrated that E-cadherin 19 and MAdCAM-1 18 are able to costimulate T cell proliferation, but again this may not be sufficient as E-cadherin and MAdCAM-1 are poor stimulators of antitumor activity against EL-4 cells. Other key recognition or signalling events mediated by the CAMs must clearly be involved to stimulate efficient anti-tumor activity. CAMs, like ICAM-1 and VCAM-1 that cause tumor rejection, induce the upregulation of CD28 and CTLA-4 on T cells, 31 and potentially other signalling molecules such as cytokines like GM-CSF 32 that may enhance T cell costimulation and tumor rejection.
The mechanism of CIL-mediated anti-tumor immunity Adoptive transfer of splenocytes from cured mice into recipient animals confirmed that CIL anti-tumor activity
Figure 6 Costimulatory CAMs play a role in facilitating cell lysis by antitumor CTL. (a) CAM expression on EL-4 cells recovered from treated tumors. EL-4 cells isolated from the tumors of B7.1, B7.2, ICAM-1, MAd-CAM-1, and E-cadherin-treated mice 2 days following gene transfer were stained with mAbs specific for the individual CAMs (thick lines), and with an isotype-matched control mAb (thin line). Cotransfection with GFP was used to estimate efficiency of transfection with the hu-E-cadherin expression vector.
was mediated by cellular immunity. Antibody depletion of leukocyte subsets revealed that the anti-tumor immune response was largely mediated by CD8 + T cells and NK cells, as has been noted previously for B7.1 and ICAM-1-mediated anti-tumor immunity. 33 Both NK and CD8 + T cells may be necessary to kill EL-4 cells that express different levels of MHC class I, where NK cells would be expected to kill EL-4 cells expressing little or no MHC class I. The EL-4 cells used in the present study contained mixed populations either expressing or lacking MHC class I (Figure 8 ). There was a minor contribution from CD4 + T cells, in accord with the fact that some EL-4 cells expressed MHC class II molecules (Figure 8 ). Of note was the fact that the nature of the anti-tumor immune response appeared identical regardless of the identity of the costimulatory molecule used for gene transfer. It is possible that B7.1, B7.2, VCAM-1, ICAM-1 or MAdCAM-1 function by initially breaking tolerance or overcoming immunological ignorance of the tumor leading to tumor cell lysis, but from thereafter the CAMs become 
(b) Shown is a representative experiment in which parental EL-4 cells and cells isolated from the tumors of B7.1, B7.2, ICAM-1, MAdCAM-1, and E-cadherin-treated mice 2 days following gene transfer were mixed in different effector to target (E:T) ratios with splenocytes from B7.1-treated mice. Cyotoxicity assays were also performed in the presence of saturating concentrations of antibodies to each costimulatory CAM, or rat IgG control antibody (latter control shown only for VCAM-1, but similar results obtained for other CAMs)
. Similar cytotoxicity profiles were obtained with splenocytes isolated from mice treated with the other costimulatory CAMs. ** Indicates a highly significant difference at P Ͻ 0.001 from control groups of mice.
superfluous as tumor antigens are presented by professional APCs resulting in a common mechanism of tumor destruction. However, a detailed analysis of the tumor infiltrate will be required to determine whether the different CAMs elicit different immune mechanisms. A previous study had noticed that mouse B7.1 was superior to mouse B7.2 in the induction of anti-tumor immunity in a mouse model of leukemia, but this was not the case in our tumor model where the human homologue of B7.2 was employed. 34 Anti-tumor CTL activity stimulated by each of the costimulatory CAMs involved both the perforin and Fasligand pathways, where the Fas-ligand pathway predominated. Treatment of cells with a combination of EGTA and anti-Fas-ligand mAb to block both pathways, almost completely inhibited the activity of anti-tumor CTLs. Residual cytolytic activity that remained may be due either to incomplete inhibition of the perforin and Fas-ligand pathways or to TNF-␣-mediated cytotoxicity, as B7.1 and ICAM-1 have been shown to induce cytotoxic levels of TNF on T cells. 35 In summary, these results demonstrate that multiple xenogeneic CILs have therapeutic potential in the treatment of immunogenic cancers. Optimized gene transfer of xenogeneic CILs is a very potent method for causing the rejection of small tumors, and could be used in combination with tumor-size reducing agents such as cell cycle inhibitors, anti-angiogenic agents, and chemotherapy for the treatment of advanced cancer. CILs could be used to supplement, enhance or supercede conventional DC adoptive immunotherapy of cancer.
Materials and methods
Mice and cell lines Female C57BL/6 mice, 6-8 weeks old, were obtained from the Animal Resource Unit, School of Medicine and Health Science, University of Auckland, Auckland, New Zealand. The EL-4 thymic lymphoma, which is of C57BL/6 (H-2b) origin was purchased from the American Type Culture Collection (Rockville, MD, USA). It was cultured in vitro at 37°C in DMEM medium (Gibco BRL, Grand Island, NY, USA), supplemented with 10% foetal calf serum, 50 U/ml penicillin/streptomycin, 2 mm l-glutamine, 1 mm pyruvate. The cell line was heterogeneous with regard to MHC expression, where subpopulations either expressed or lacked MHC class I and II molecules (Figure 8 ).
Antibodies and cDNAs
Mouse hybridomas secreting mAbs against human VCAM-1 (VIII-6G10 mAb), 36 mouse CD8 (53-6.72 mAb), CD4 (Gk1.5 mAb), and NK cells (PK136 mAb) were purchased from the American Type Culture Collection. The rat hybridoma cell line MECA-367 37 which secretes a mAb against mouse MAdCAM-1 was kindly provided by Dr Eugene Butcher, Stanford University, Stanford, CA, USA. The polyclonal anti-mouse E-cadherin antiserum has been described elsewhere. 19 A rabbit polyclonal antibody against human MAdCAM-1 was raised to a MAd-CAM-1-GST fusion protein encoding nucleotides 272 to 562 of the published sequence 38 (accession No. U82483). Antibodies against mouse B7.1 (1G10), human B7.2 (IT2.2), and human ICAM-1 (HA58) were purchased from Pharmingen, San Diego, CA, USA. Anti-mouse MHC Class I (H58A) and II (TH81A5) mAbs were purchased from Veterinary Medical Research Development, Pullman, WA, USA. The 2G5 mAb to human HML-1 was obtained from Immunotech, Marseille, France). Complementary DNA encoding full-length human VCAM-1 was purchased from R&D Systems, Abingdon, UK; B7. by Dr J Ni, Human Genome Sciences, Rockville, MD, USA; mouse B7.1 13 was provided by Dr P Linsley, BristolMyers-Squibb, Seattle, WA, USA; mouse MAdCAM-1 40 was generously donated by Dr Eugene Butcher, Stanford University; mouse E-cadherin 41 was provided by Dr M Takeichi, Kyoto University, Kyoto, Japan; whereas human E-cadherin 42 was kindly donated by Drs D Rimm and J Morrow, Yale University School of Medicine, New Haven, CT, USA. We have previously reported the cloning and characterization of human MAdCAM-1 cDNA. 38 Gene transfer of CILs and measurement of anti-tumor systemic immunity Plasmid expression vectors in pCDM8 were prepared by cesium chloride gradient centrifugation, and diluted to 600 g/ml in a solution of 5% glucose in 0.01% Triton X-100, unless indicated otherwise. They were mixed in a ratio of 1:3 (wt:wt) with DOTAP cationic liposomes (Boehringer Mannheim, Mannheim, Germany). Tumors were established by injection of 1 × 10 5 EL-4 tumor cells into the left flank of mice, and growth determined by measuring two perpendicular diameters. Animals were killed when tumors reached more than 1 cm in diameter, in accord with Animal Ethics Approval (University of Auckland). Tumors reached 0.1 to 0.3 cm in diameter after approximately 14 days, and were injected at multiple sites with 100 l of DNA (60 g) per liposome complex. Cured mice were rechallenged 3 weeks after gene transfer by injecting either 1 × 10 5 or 5 × 10 7 EL-4 cells (0.1 ml) subcutaneously into the opposing flank (right flank). All experiments included six mice per treatment group and each experiment was repeated at least once. Statistical analysis was determined by the Student t test, where P Ͻ 0.05 was considered significant, and P Ͻ 0.001 highly significant.
Immunohistochemistry
Tumor cryosections (10 m) made 2 days following gene transfer were blocked with horse serum and stained with anti-CAM mAbs using the VECTASTAIN Universal Quick kit (Vector Laboratories, Burlingame, CA, USA). They were developed with Sigma FAST DAB (3, 3Ј-diaminobenzidine tetrahydrochloride) with CoCl 2 enhancer tablets (Sigma). Tissue sections were also treated with the 1G10 mAb, then FITC-conjugated goat anti-rat IgG (Sigma), and examined by fluorescence microscopy.
FACScan analysis of CAM gene expression Tumors were excised 2 days following gene transfer, and a single cell suspension prepared by collagenase digestion. Tumor cells were cultured for a further 2 days and stained with anti-CAM mAbs, and FITC-conjugated goat anti-rat IgG (Sigma); or with the FITC-labelled isotypematched control IgG2a mAb 2G5 to human HML-1, and evaluated by flow cytometry. Since we have no antibody reagent against human E-cadherin, transfection efficiency of the human E-cadherin expression vector was estimated by cotransfection with the pAAV/CMV-GFP vector. Green fluorescence for GFP expression was recorded in the FITC emission channel. Cells transfected with empty vector alone served as controls.
Adoptive transfer of CIL-stimulated CTL Splenocytes isolated as described previously 43 were resuspended in Hank's balanced salt solution containing 1% FCS, and stimulated with 5 g/ml PHA and 100 U/ml recombinant mouse IL-2 for 4 to 5 days. Animals bearing tumors, established for 14-20 days, received both intratumoral and intraperitoneal (i.p.) injections of 2 × 10 8 cultured splenocytes.
Cytotoxicity assays
Splenocytes were harvested 28 days following initial gene transfer, or 42 days after a parental tumor challenge, and incubated at 37°C with EL-4 target cells in graded E:T ratios in 96-well round-bottom plates. After a 4-h incubation, 50 l of supernatant was collected, and lysis was measured using the Cyto Tox 96 Assay Kit (Promega, Madison, WI, USA). Background controls for non-specific target and effector cell lysis were included. After background subtraction, percentage of cell lysis was calculated using the formula: 100 × (experimentalspontaneous effector-target spontaneous target/ maximum target-spontaneous target). The roles of the Fas ligand and perforin pathways in facilitating tumor cell lysis was tested by pre-incubating the effector CTL with 12 g/ml Fas ligand neutralizing antibody MFL3 (Pharmingen, San Diego, CA, USA) at 37°C; and by adding 5 mm EGTA/4 mm MgCl 2 to mixes of the target and effector cells, respectively.
Analysis of the roles of CIL in tumor cell lysis Tumors were excised 2 days following gene transfer, and injected with 110 U collagenase (1.1 ml), and tumor cells isolated by homogenization, further collagenase treatment, and centrifugation. Cells were cultured for 6 days, and the levels of expression of CILs and B7 molecules assessed by FACScan analysis. They were then used as CTL targets as described above.
Depletion of leukocyte subsets
Mice were depleted of CD8 + , and CD4 + T cells and NK cells by i.p. and intravenous injection 4 days before gene transfer, and thereafter every alternate day with 300 g (0.1 ml) of the 53-6.72 (anti-CD8), Gk1.5 (anti-CD4), and PK136 (anti-NK) mAbs. Rat IgG (Sigma) was used as a control antibody. Antibodies were an ammonium sulphate fraction of ascites, which titered to at least 1:2000 by FACS (Becton Dickinson, San Jose, CA, USA) staining splenocytes. Depletion of individual leukocyte subsets was found to be more than 90% effective, as determined by FACScan analysis.
Statistical analysis
Results were expressed as mean values ± standard deviation (s.d.), and a Student's t test was used for evaluating statistical significance. A value less than 0.05 (P Ͻ 0.05) was used for statistical significance.
